Evidence map›Paper›PMID 25860346›Full record

ArticleJournal of neurology2015

Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes.

Jordi A Matías-Guiu, María Nieves Cabrera-Martín, Teresa Moreno-Ramos, María Valles-Salgado, Marta Fernandez-Matarrubia, José Luis Carreras, Jorge Matías-Guiu

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.European journal of nuclear medicine and molecular imaging · 2018
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Neuroimaging in Dementia.Seminars in neurology · 2017
    Review
  19. SAND: a Screening for Aphasia in NeuroDegeneration. Development and normative data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jordi A Matías-GuiuDepartment of Neurology, Hospital Clínico San Carlos, San Carlos Institute for Health Research (IdISSC), Complutense University of Madrid, Calle Profesor Martín Lagos, S/N, 28040, Madrid, Spain, jordimatiasguiu@hotmail.com.
María Nieves Cabrera-Martín
Teresa Moreno-Ramos
María Valles-Salgado
Marta Fernandez-Matarrubia
José Luis Carreras
Jorge Matías-Guiu
Universidad Complutense de Madrid · ESHospital Clínico San Carlos · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The logopenic variant of primary progressive aphasia (lvPPA) has been associated with Alzheimer disease, although this relationship is still subject to debate. The purpose of this study is to determine the frequency of amyloid biomarkers in patients with lvPPA, and record any potential clinical or topographic differences between patients with and without amyloid deposits. We conducted cognitive examination and positron-emission tomography studies with fluorodeoxyglucose ((18)F) and florbetapir ((18)F) in a cohort of 16 patients diagnosed with lvPPA. We evaluated the prevalence of amyloid deposits as well as any clinical and metabolic differences between the groups with and without significant presence of amyloid deposits. Eleven patients (69 %) were considered amyloid-positive. The amyloid-positive group displayed less metabolic activity in the left temporoparietal region than the control group, while the amyloid-negative group showed lower metabolism in the left temporoparietal region extending to the anterior temporal and basal frontal regions. The percentage of change in patients with clinical and FDG-PET follow-up did not differ between the amyloid-positive and amyloid-negative subgroups. The frequency of amyloid-positive cases confirms that lvPPA is frequently associated with Alzheimer disease. Amyloid-negative patients show a different cerebral metabolic pattern. These findings show the relevance of using amyloid PET to study lvPPA, and also suggest that the logopenic variant may not be specific to Alzheimer disease in certain cases.

Indexed as

Aphasia, Primary ProgressiveFluorodeoxyglucose F18Positron-Emission TomographyAgedAged, 80 and overAmyloidBrain MappingCognition DisordersFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsStatistics, NonparametricTomography, X-Ray ComputedAmyloidFluorodeoxyglucose F18

Identifiers

PMID25860346
OpenAlexW2012039814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.